It looks like France’s Constitutional Council is giving CBD its blessing, saying that CBD is not harmful to health nor addictive. This contradicts a December decree which prohibited the possession, use, or sale of CBD. Continue reading “France’s Constitutional Council Gives CBD the Nod”
Tilray, Inc. (TLRY), now Tilray Brands, Inc., announced good news during its Q2 fiscal 2022 earnings call.
CEO Irwin Simon applauded Tilray’s ability to maintain status with the #1 cannabis market share in Canada. In addition, he said, “Our second quarter performance reflects notable success building high-quality and highly sought-after cannabis and lifestyle CPG brands.” Continue reading “Tilray Maintains #1 Position in Canada”
A recent study by Oregon State University (OSU) and Oregon Health and Science University uncovered two chemicals that may protect human cells from COVID-19 infections. These chemicals are found in live cannabis plants. Continue reading “Can Cannabis Help Fight COVID?”
2022 doesn’t look like it will be the year that the U.S. legalizes cannabis on a federal level. Unfavorable political dynamics in Washington D.C. have put a black could over the industry. Continue reading “Cannabis Legalization In 2022 Looks Doubtful”
According to Organigram (OGI), Canadian adult-use sales are on the rise. The company’s sales rocketed more than 70% in the same period YoY. Quarterly net revenue topped $30M (CAD). Continue reading “Organigram Sees Spike in Adult-Use Sales”
It’s no secret that Tilray’s cannabis sales have been dropping in Canada. In the quarter that ended Nov. 30, Tilray (TLRY) reported net revenue of $155.1M. This figure is considerably lower than consensus expectations of $170M. Tilray correlates the miss with coronavirus-related headwinds, supply-chain issues, and a lower share of the key Canadian market.
Even though Germany’s government has its eyes set on tackling the coronavirus pandemic, some details of the forthcoming cannabis legalization plan have been released.
A top government official has provided additional information about the pending proposal. Continue reading “German Government Official Previews Cannabis Legalization”
The three largest cannabis producers in Canada just had their 2022 sales forecasts cut by hundreds of millions of dollars.
Tilray (TLRY), Canopy (CGC), and Aurora (ACB) have come under pressure from falling stock prices, poor execution by executive teams, and an increasingly competitive landscape across the adult-use industry.
While most lenders have restrained from servicing or extending credit to the state-licensed cannabis industry, StandardC’s lending network has broken new ground, offering cost-effective financing.
StandardC’s lending partner has extended a $5 million loan from their newly established $200M fund to a leading marijuana cultivator in a groundbreaking move.
Robert Mann, CEO of StandardC, said, “for too long, the cannabis industry has been unable to obtain loans and lines of credit without paying a ‘Cannabis Tax’ where lenders charge exorbitant interest and fees. Our network is enabling a consortium of lenders that can offer cost-effective real estate loans, lines of credit, and more.”
For more than 50 years, there has only been one DEA-approved facility legally allowed to grow cannabis for research purposes.
However, in May of 2020, several companies received conditional approvals for their applications after the DEA said it would be taking steps to end that monopoly and authorize additional manufacturers.